We interpret these findings as the consequence of the insertional mutagenesis event, a risk that is potentially associated with retrovirally mediated gene transfer and that has previously been considered to be very low in humans. 4 For this reason, a thorough reassessment of the potential risk of retrovirally mediated gene therapy is warranted. It is likely that additional factors may have contributed to the adverse event in our patient, including a varicella-zoster virus infection five months before clinically detectable lymphoproliferation, which may have stimulated immune reactivity of the g / d T-cell clone, or a selective growth advantage conferred by g c expression in the transduced cells. Genetic predisposing factors for childhood cancer are also possible, since medulloblastomas have developed in the proband's sister and a first-degree relative.
We have proposed to the French regulatory authorities a halt to our trial until further evaluation of the causes of this adverse event and a careful reassessment of the risks and benefits of continuing our study of gene therapy in patients with X-linked severe combined immunodeficiency can be completed. The latter will include a comparison with the outcome of the only available alternative therapy, haploidentical stem-cell transplantation. 5 Salima Hacein-Bey-Abina, Pharm.D., Ph.D. showed that warfarin with or without aspirin, as compared with aspirin alone, was associated with a reduction in the risk of the composite end point of death, nonfatal myocardial infarction, or embolic stroke in patients with myocardial infarction but did not establish its clinical relevance. They did not assess the implications of the components of the end point for patients. As compared with aspirin alone, the absolute reduction in the rate of nonfatal myocardial infarction with warfarin alone was 0.6 percent per year and with warfarin plus aspirin was 1.1 percent. Patients are not likely to accept long-term warfarin therapy for such a modest reduction in a nondisabling, nonfatal condition. A similar reduction in the rate of events such as death or stroke is more likely to lead to acceptance of warfarin therapy. Hurlen et al., however, found no reduction in mortality and found a reduction in the rate of stroke of 0.3 percent per year with both warfarin and warfarin plus aspirin -too small to change clinical practice. to the editor: Hurlen et al. found warfarin, alone or in combination with aspirin, to be superior to aspirin alone after acute myocardial infarction. Becker, in the accompanying editorial, 1 concluded on the basis of this and another study (the Antithrombotics in the Prevention of Reocclusion in Coronary Thrombolysis 2 trial 2 ) that anticoagulation therapy should be "strongly considered" after acute myocardial infarction.
We believe that the general applicability of the findings of these two trials is severely limited by the restricted use of coronary intervention. American College of Cardiology-American Heart Association guidelines 3 recommend coronary angiography for patients with acute myocardial infarction associated with ST-segment elevation who have spontaneous or provocable ischemia and for most patients with acute myocardial infarction not associated with ST-segment elevation, who clearly benefit from an early, aggressive approach. The value of warfarin has been demonstrated in patients who, for the most part, do not undergo early coronary intervention. Conceivably, anticoagulation may be beneficial in patients who leave the hospital with severe narrowing of the infarct-related artery, but it may not be as beneficial in patients who are discharged af-
